Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

Sort:Best matchNewest Highest certainty Download CSV

No studies found 5 · 62.5%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 1 · 12.5%High 0 · 0%

Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery plus WBRT

Progression‐free survival · people with single or solitary brain metastasis

Surgery plus whole brain radiotherapy (WBRT) showed no clear difference in progression‐free survival compared with stereotactic radiosurgery plus WBRT (low certainty).

1 finding from 1 review

Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis 2018 · Cochrane Headline outcomes only
RR 0.55 [0.22, 1.38]
1 study · 21 participants
Low

Surgery plus whole brain radiotherapy (WBRT) vs stereotactic radiosurgery

Progression‐free survival ‐ not measured · people with single or solitary brain metastasis

The review found no eligible studies for this question.

1 finding from 1 review

Surgery versus stereotactic radiotherapy for people with single or solitary brain metastasis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oestrogen therapy alone vs placebo

Progression‐free survival (PSF) · women previously treated for endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

Hormone replacement therapy for women previously treated for endometrial cancer 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.43 [1.06, 1.93]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 0.53 [0.31, 0.91]
1 study · 95 participants
Moderate

Neuronavigation image‐guided surgery vs surgery

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

1 finding from 1 review · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

iMRI image‐guided surgery vs surgery

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

1 finding from 1 review · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

5‐ALA image‐guided surgery vs surgery

Progression‐free survival · high‐grade glioma

The review found no eligible studies for this question.

1 finding from 1 review · compare the 2 reviews

Intraoperative imaging technology to maximise extent of resection for glioma: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found